Lam Research Corporation — 7.6/10

Lam Research is a wafer-fab-equipment (WFE) pure-play in etch, deposition, and clean. It is the clear #1 in dry etch (~50-55% share) and #2 in deposition, inside an etch market where the top three players (Lam / Applied Materials / TEL) control ~90% of revenue. Its tools are qualified as "process of record" per node — a customer cannot swap Lam out inside 12 months (multi-year, multi-hundred-million-dollar requalification). A 36%-of-revenue services annuity (CSBG) sits on top of the industry's largest installed base (>100k chambers).

The thesis is a quality compounder / "leaders remain leaders" story. Revenue is re-accelerating off the FY2024 WFE trough (+23.8% YoY in cal 2026Q1), GAAP operating margin has expanded ~710bps to a record 35.0%, FCF is growing at ~29% margin on a net-cash balance sheet, and management (Archer/Bettinger — the most stable long-tenured pair in semicap) has beaten the midpoint on 20 of 20 guided metrics over five quarters. The quality gate passes on all three tests. The composite is held to 7.6/10 by two drags: the street already prices the entire bull case (Sentiment 3/10) and ~34% of revenue is exposed to U.S.-China export-control policy (Concerns 4/10).

A best-in-class semicap franchise that earns a genuine 7.6/10 BUY on the "leaders remain leaders" quality-compounder thesis. Three dimensions carry it: near-textbook financials (9/10 — +23.8% YoY revenue re-acceleration, ~710bps of operating-margin expansion to a record 35.0%, +27% FCF growth on a net-cash balance sheet), decisive oligopoly positioning (Thematic 8/10 — clear #1 in dry etch inside a top-3 ~90% market), and best-in-class management (9/10 — 20 of 20 guided metrics beat, clean beat-and-raise).

Quality gate: PASS (0 NOs). Oligopoly YES (~50-55% etch share, price-setter at the leading edge). Positive and growing FCF YES ($5.41B FY2025, +27% YoY). Management 3+ year track record YES (Archer/Bettinger, zero turnover). All three YES → no cap; the composite stands at its unadjusted 7.60.

Two drags keep this out of the high-7s / low-8s: on the inverted sentiment axis LRCX is the textbook crowded consensus long (3/10 — no management-street divergence to exploit, price above target, FY27 +33% priced in), and the concerns dimension is capped by ~34% China revenue exposure under a live export-control overhang plus a FY27 P/E modestly above peers (4/10).

LRCX is the dominant etch leader where it matters most — ~50-55% share in dry etch, tools embedded as "process of record" in customer roadmaps, and pricing power visible in 50%+ gross margins and ~35% EBIT margins. The financial and management profiles are top-decile, and the AI-driven WFE supercycle (WFE guided to ~$140B in CY2026 with upside bias) gives the theme multi-year visibility. Under the quality-gate framework, all three hard tests pass, so the score is not capped.

The binding constraints are on the setup, not the business. Management's bull case is fully voiced, fully modeled, and fully priced — the street is pushing management to be more aggressive, not less, so there is no differentiated insight to exploit and no valuation cushion (FY27 P/E ~46x vs. ~40-42x peers). And ~34% of revenue sits in China under the BIS affiliate rule / export controls; direction is favorable (China share fell from 43% to 34% in three quarters) but the absolute exposure is >3x the rubric's line.

Net: a high-quality compounder where the quality is largely recognized. The 7.6 rewards the franchise, financials, and management; the sentiment and concerns scores dock it for a lack of edge and a large policy-exposed geography, not for any operational weakness.